Written Narrative / Presentation Script
Evidence-Based Management of Acute Vaso-Occlusive Pain Crisis
in Adults With Sickle Cell Disease
Ryesha Gipson, RN
Capella University | NURS-FPX4025
Instructor: B. Dvorak | September 30, 2026
Introduction
Hello, my name is Ryesha Gipson. Today I will present my evidence-based practice poster on the
management of acute vaso-occlusive pain crisis in adults with sickle cell disease. My selected
Sentinel U patient is Jamie Hampton, a Level 2 patient with sickle cell anemia who is recovering
from an acute pain crisis.
I selected this diagnosis because pain management is a major component of nursing care for
patients experiencing a sickle cell vaso-occlusive crisis. These patients may require frequent pain
assessments, intravenous pain medication, hydration, and close monitoring for serious
complications. My presentation focuses on how standardized and multimodal pain-management
strategies can be used to improve the care of adults experiencing an acute vaso-occlusive crisis.
Background and Diagnosis
Sickle cell disease is an inherited blood disorder involving abnormal hemoglobin. The abnormal red
blood cells can become rigid and sickle-shaped. These cells can interfere with normal blood flow
and contribute to vaso-occlusion. When blood flow is obstructed, tissues may not receive adequate
oxygen, leading to severe pain and other complications.
Painful vaso-occlusive crises are a hallmark of sickle cell disease and can be frequent and
debilitating. Opioids remain a major treatment for acute vaso-occlusive pain, but escalating opioid
doses can create challenges, including adverse effects and inadequate pain relief in some patients.
This is one reason researchers have investigated standardized protocols and multimodal
approaches that combine opioid and non-opioid strategies.
For Jamie Hampton, this information is especially relevant because the Sentinel U case identifies
sickle cell anemia and recovery from an acute pain crisis. Her care requires continued assessment
of pain, response to treatment, hydration status, and possible complications.
PICOT Question
My PICOT question is: In adults with sickle cell disease experiencing an acute vaso-occlusive pain
crisis, how does standardized multimodal pain management, compared with traditional or usual pain
management, affect pain intensity and acute-care outcomes during hospitalization?
The population is adults with sickle cell disease experiencing an acute vaso-occlusive pain crisis.
The intervention is standardized multimodal pain management. The comparison is traditional or
usual pain management. The outcomes are pain intensity and acute-care outcomes, and the time
frame is during the acute hospitalization or acute-care encounter.
, To answer this question, I reviewed quantitative research examining standardized pain-management
protocols and ketamine as an adjunct to conventional pain treatment.
Study 1: Wachnik et al. (2022)
The first article is by Wachnik and colleagues and was published in Pain Medicine in 2022. This was
an original quantitative research article evaluating a standardized emergency department order set
for adults with sickle cell disease. The project used a pre- and post-implementation quality-
improvement design.
The standardized order set provided a multimodal approach to pain management. After
implementation, hospital admission decreased from 51 percent to 38 percent. The average time to
the first non-opioid analgesic decreased from 207 minutes to 136 minutes. Opioid exposure also
decreased, while the 72-hour emergency department return rate remained essentially unchanged.
This study is important to my PICOT question because it directly examines a standardized
multimodal approach instead of relying only on usual, nonstandardized treatment. It suggests that
having a consistent treatment process may improve selected acute-care outcomes.
A limitation is that this was not a randomized controlled trial. It was a quality-improvement project
using a before-and-after design, so other factors may have contributed to the outcomes. Even with
that limitation, the study provides useful evidence for improving the organization and consistency of
acute sickle cell pain care.
Study 2: Kenney et al. (2022)
The second article is by Kenney and colleagues and was also published in Pain Medicine in 2022.
This was a quantitative retrospective observational study involving 56 adults hospitalized with sickle
cell vaso-occlusive crisis.
The researchers examined the timing of sub-anesthetic ketamine infusion. Patients who received
ketamine earlier in hospitalization were compared with patients who received it later. Earlier initiation
was associated with greater short-term reductions in pain intensity at one and two days. However,
the researchers did not find a statistically significant reduction in opioid consumption.
This article is relevant because ketamine represents an adjunctive component of multimodal pain
management. The findings suggest that timing may matter and that earlier use of an adjunctive
therapy may improve short-term pain control for selected patients.
However, this study also has limitations. It was retrospective and observational rather than
randomized. Therefore, the findings show an association between earlier ketamine and improved
short-term pain scores but do not prove that ketamine alone caused the improvement. This
distinction is important when applying the findings to clinical practice.
Study 3: Froomkin et al. (2022)
The third article is by Froomkin and colleagues and was published in Hospital Pharmacy. It was an
original quantitative, single-center retrospective observational study. The researchers evaluated 12
adults with sickle cell vaso-occlusive crisis who received ketamine infusion along with standard
opioid therapy. The study included 24 ketamine-treated admissions, and patients were compared
with their own previous vaso-occlusive crisis hospitalization.
Evidence-Based Management of Acute Vaso-Occlusive Pain Crisis
in Adults With Sickle Cell Disease
Ryesha Gipson, RN
Capella University | NURS-FPX4025
Instructor: B. Dvorak | September 30, 2026
Introduction
Hello, my name is Ryesha Gipson. Today I will present my evidence-based practice poster on the
management of acute vaso-occlusive pain crisis in adults with sickle cell disease. My selected
Sentinel U patient is Jamie Hampton, a Level 2 patient with sickle cell anemia who is recovering
from an acute pain crisis.
I selected this diagnosis because pain management is a major component of nursing care for
patients experiencing a sickle cell vaso-occlusive crisis. These patients may require frequent pain
assessments, intravenous pain medication, hydration, and close monitoring for serious
complications. My presentation focuses on how standardized and multimodal pain-management
strategies can be used to improve the care of adults experiencing an acute vaso-occlusive crisis.
Background and Diagnosis
Sickle cell disease is an inherited blood disorder involving abnormal hemoglobin. The abnormal red
blood cells can become rigid and sickle-shaped. These cells can interfere with normal blood flow
and contribute to vaso-occlusion. When blood flow is obstructed, tissues may not receive adequate
oxygen, leading to severe pain and other complications.
Painful vaso-occlusive crises are a hallmark of sickle cell disease and can be frequent and
debilitating. Opioids remain a major treatment for acute vaso-occlusive pain, but escalating opioid
doses can create challenges, including adverse effects and inadequate pain relief in some patients.
This is one reason researchers have investigated standardized protocols and multimodal
approaches that combine opioid and non-opioid strategies.
For Jamie Hampton, this information is especially relevant because the Sentinel U case identifies
sickle cell anemia and recovery from an acute pain crisis. Her care requires continued assessment
of pain, response to treatment, hydration status, and possible complications.
PICOT Question
My PICOT question is: In adults with sickle cell disease experiencing an acute vaso-occlusive pain
crisis, how does standardized multimodal pain management, compared with traditional or usual pain
management, affect pain intensity and acute-care outcomes during hospitalization?
The population is adults with sickle cell disease experiencing an acute vaso-occlusive pain crisis.
The intervention is standardized multimodal pain management. The comparison is traditional or
usual pain management. The outcomes are pain intensity and acute-care outcomes, and the time
frame is during the acute hospitalization or acute-care encounter.
, To answer this question, I reviewed quantitative research examining standardized pain-management
protocols and ketamine as an adjunct to conventional pain treatment.
Study 1: Wachnik et al. (2022)
The first article is by Wachnik and colleagues and was published in Pain Medicine in 2022. This was
an original quantitative research article evaluating a standardized emergency department order set
for adults with sickle cell disease. The project used a pre- and post-implementation quality-
improvement design.
The standardized order set provided a multimodal approach to pain management. After
implementation, hospital admission decreased from 51 percent to 38 percent. The average time to
the first non-opioid analgesic decreased from 207 minutes to 136 minutes. Opioid exposure also
decreased, while the 72-hour emergency department return rate remained essentially unchanged.
This study is important to my PICOT question because it directly examines a standardized
multimodal approach instead of relying only on usual, nonstandardized treatment. It suggests that
having a consistent treatment process may improve selected acute-care outcomes.
A limitation is that this was not a randomized controlled trial. It was a quality-improvement project
using a before-and-after design, so other factors may have contributed to the outcomes. Even with
that limitation, the study provides useful evidence for improving the organization and consistency of
acute sickle cell pain care.
Study 2: Kenney et al. (2022)
The second article is by Kenney and colleagues and was also published in Pain Medicine in 2022.
This was a quantitative retrospective observational study involving 56 adults hospitalized with sickle
cell vaso-occlusive crisis.
The researchers examined the timing of sub-anesthetic ketamine infusion. Patients who received
ketamine earlier in hospitalization were compared with patients who received it later. Earlier initiation
was associated with greater short-term reductions in pain intensity at one and two days. However,
the researchers did not find a statistically significant reduction in opioid consumption.
This article is relevant because ketamine represents an adjunctive component of multimodal pain
management. The findings suggest that timing may matter and that earlier use of an adjunctive
therapy may improve short-term pain control for selected patients.
However, this study also has limitations. It was retrospective and observational rather than
randomized. Therefore, the findings show an association between earlier ketamine and improved
short-term pain scores but do not prove that ketamine alone caused the improvement. This
distinction is important when applying the findings to clinical practice.
Study 3: Froomkin et al. (2022)
The third article is by Froomkin and colleagues and was published in Hospital Pharmacy. It was an
original quantitative, single-center retrospective observational study. The researchers evaluated 12
adults with sickle cell vaso-occlusive crisis who received ketamine infusion along with standard
opioid therapy. The study included 24 ketamine-treated admissions, and patients were compared
with their own previous vaso-occlusive crisis hospitalization.